TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells

Oncotarget

Volumn 5, Issue 20, 2014, Pages 10127-10139

  Sutton, S K ^a   Koach, Jessica ^a   Tan, Owen ^a   Liu, Bing ^a   Carter, Daniel R ^a   Wilmott, James S ^b   Yosufi, Benafsha ^b,c   Haydu, Lauren E ^c   Mann, Graham J ^b,c   Thompson, John F ^c   Long, Georgina V ^b   Liu, Tao ^a   McArthur, Grant ^d,e   Zhang, Xu Dong ^f   Scolyer, Richard A ^b,c   Cheung, Belamy B ^a   Marshall, Glenn M ^a,g  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

BRAF inhibitor; Cell migration; IFN 1; Melanoma; TRIM16

Indexed keywords

B RAF KINASE; BETA1 INTERFERON; DABRAFENIB; PROTEIN TRIM16; TUMOR PROTEIN; UNCLASSIFIED DRUG; VEMURAFENIB; BETA INTERFERON; DNA BINDING PROTEIN; INDOLE DERIVATIVE; SULFONAMIDE; TRANSCRIPTION FACTOR; TRIM16 PROTEIN, HUMAN;

ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COHORT ANALYSIS; DNA METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL LINE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN STABILITY; BIOSYNTHESIS; CELL MOTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SKIN NEOPLASMS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA-BINDING PROTEINS; HUMANS; INDOLES; INTERFERON-BETA; MELANOMA; PROMOTER REGIONS, GENETIC; SKIN NEOPLASMS; SULFONAMIDES; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84930468254     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2466     Document Type: Article

References (35)

1. Miller A, Mihm Jr. MC, Melanoma. N Engl J Med. 2006; 355:51-65.
2. Cummins D, Cummins, JM., Pantle H., Silverman MA., Leonard AL, Chanmugam, A. Cutaneous malignant melanoma. Mayo Clin Proc. 2006; 81:500-507.
3. Gogas H, Kirkwood, JM, Sondak, VK. Chemotherapy for metastatic melanoma. Cancer. 2007; 109:455-464.
4. Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
5. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012; 379: 1893-1901.
6. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr., Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380:358-365.
7. Jang S Atkins, MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet. 2013; 14:e60-e69.
8. Flaherty K, Hodi, FS., Fisher, DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012; 12:349-361.
9. Cambiaghi V, Giuliani V, lombardi S, Marinelli C, Toffalorio F, Pelicci P. TRIM proteins in cancer. Advances in Experimental Medicine and Biology. 2012; 770:77-91.
10. Hatakeyama S. TRIM proteins and cancer. Nature Reviews Cancer. 2011; 11:792-804.
11. Munding C, Keller M, Niklaus G, Papin S, Tschopp J, Werner S, Beer H. The estrogen-responsive b box protein: a novel enhancer of interleukin-1beta secretion. Cell Death Differ. 2006; 13:1938-1949.
12. Beer H, Munding C, Dubois N, Mamie C, Hohl D, Werner S. The estrogen-responsive b box protein. J Biol Chem. 2002; 277:20740-20749.
13. Cheung B, Koach J, Tan O, Kim P, Bell J, D'andreti C, Sutton S, Malyukova A, Sekeyre E, Norris M, Haber M, Kavallaris M, Cunningham A, Proby C, Leigh I, Wilmott J, et al. The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. The Journal of Pathol. 2012; 226:451-462.
14. Marshall G, Bell J, Koach J, Tan O, Kim P, Malyukova A, Thomas W, Sekyere E, Liu T, Cunningham A, Tobias V, Norris M, Haber M, Kavallaris M, Cheung B. TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells. Oncogene. 2010; 29:6172-6183.
15. Borden E, Jacobs B, Hollovary E, Rybicki L, Elson P, Olencki T, Triozzi P. Gene regulatory and clinical effects of interferon-beta in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res. 2011; 31: 433-440.
16. Fountain J, Karayiorgou M, Taruscio D, Graw S, Buckler A, Ward D, Dracopoli N, Housman D. Genetic and physical map of the interferon region on chromosome 9p. Genomics. 1992; 14:105-112.
17. Maccioni L, Rachakonda P, Bermejo J, Planelles D, Requena C, Hemminki K, Nagore E, Kumar R. Variants at the 9p21 locus and melanoma risk. BMC Cancer. 2013; 13:1-15.
18. Merkel C, Medrano, RFV., Barauna, VG., Strauss, BE. Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo. Cancer Gene Ther. 2013; :1-9.
19. Ryuke Y, Mizuno M, Natsume A, Suzuki O, Nobayashi M, Kageshita T, Matsumoto K, Saida T, Yoshida J. Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy. Melanoma Research. 2003; 13:349-356.
20. Kageshita T, mizuno, M., Ono, T., Matsumoto, K., Saida, T., Yoshida, J. Growth inhibition of human malignant melanoma transfected with the human interferon-beta gene by means of cationic liposomes. Melanoma Research. 2001; 11:337-342.
21. Stefanov AN, Fox J, Haston CK. Positional cloning reveals strain-dependent expression of Trim16 to alter susceptibility to bleomycin-induced pulmonary fibrosis in mice. PLoS genetics. 2013; 9:e1003203.
22. Satomi H, Wang, B., Fujisawa, H., Otsuka, F. Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner. Cytokine. 2002; 18:108-115.
23. Roh M, Zheng, Z., Kim, HS., Jeung, HC., Rha, SY., Chung, KY. Difference of interferon-alpha and interferon-beta on melanoma growth and lymph node metastasis in mice. Melanoma Research. 2013; 23:114-124.
24. Aoyagi S, Hata, H., Homma, E., Shimizu, H. Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study. Oncology. 2012; 82:139-146.
25. Panne D, Maniatis, T., Harrison, SC. An atomic model of the interferon-beta enhanceosome. Cell. 2007; 129: 1111-1123.
26. Panne D. The enhanceosome. Current Opinion in Structural Biology. 2008; 18:236-242.
27. Falvo J, Parekh, BS., Lin, CH., Fraenkel, E., Maniatis, T. Assembly of a functional beta interferon enhanceosome is dependent on ATF-2-c-jun heterodimer orientation. Mol Cell Biol. 2000; 20:4814-4825.
28. Cheung B, Bell J, Raif A, Bohlken A, Yan J, Roediger B, Poljak A, Smith S, Lee M, Thomas W, Kavallaris M, Norris M, Haber M, Liu H, Zajchowski D, Marshall G. The estrogen-responsive b box protein is a novel regulator of the retinoid signal. J Biol Chem. 2006; 281:18246-18256.
29. Forbes S, Bindal N, Bamford S, Cole C, Kok C, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague J, Campbell P, Stratton M, Futreal P. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2010; 39: 945-950.
30. Massiah MA, Simmons BN, Short KM, Cox TC. Solution structure of the RBCC/TRIM B-box1 domain of human MID1: B-box with a RING. J Mol Biol. 2006; 358: 532-545.
31. Bell J, Malyukova A, Holien J, Koach J, Parker M, Kavallaris M, Marshall G, Cheung B. TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other TRIM family members. Plos One. 2012; 7:1-9.
32. Raif A, Marshall GM, Bell JL, Koach J, Tan O, D'Andreti C, Thomas W, Sekyere E, Norris M, Haber M, Kavallaris M, Cheung BB. The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation. Cancer Lett. 2009; 277:82-90.
33. Huang C, Jacobson, K., Schaller, MD. MAP kinases and cell migration. J Cell Sci. 2004; 117:4619-4628.
34. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res. 2001; 7: 1821-1831.
35. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012; 18:1386-1394.